cas 1247119-83-0|| where to buy 2-(4-Ethylphenyl)-2-methylpropanoic acid

製品名:2-(4-Ethylphenyl)-2-methylpropanoic acid

IUPAC Name:2-(4-ethylphenyl)-2-methylpropanoic acid

包装単位	有効在庫	価格（USD）
CM532274-100mg	in stock	ȯƿƥ
CM532274-500mg	in stock	ƥǑŞ
CM532274-1g	1-2 Weeks	ƿȐƃ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1247119-83-0 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1247119-83-0; 分子式:C12H16O2; 融点:-; SMILESコード:O=C(O)C(C)(C)C(C=C1)=CC=C1CC; 密度:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Alectinib; Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.